15 May TeloView Measures Genomic Stability To Predict Disease Aggressiveness
MedicalResearch.com Interview with:
MedicalResearch.com: What is the background for 3D Signatures?
Response: 3D Signatures, and its clinical lab tests, which incorporate its proprietary TeloViewTM software analytics, is the culmination of over 20 years of ground-breaking research conducted by Dr. Sabine Mai and her colleagues. It is the only technology in the world that quantifies genomic instability, which is the hallmark of cancer and other proliferative diseases at the whole-cell level.
By measuring the degree of genomic instability from different tissues, TeloViewTM has produced clinically actionable distinctions in the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers including Alzheimer’s disease. The results have been exceptional and represent a universal biomarker platform across all disease areas that the company has investigated to date.
MedicalResearch.com: Would you briefly explain what is meant by telomeres and their prognostic significance?
Response: Telomeres are regions of repetitive DNA that cap the ends of each chromosome. They normally protect chromosomes from deterioration or abnormal rearrangement, particularly during cell division. While most clinical interest in telomeres has focused on measuring telomere length as a proxy for cellular vitality, 3D Signatures has gone further. TeloViewTM analyzes a combination of six structural parameters related to telomere organization, creating a multi-modal biomarker. The software’s analysis essentially generates a chromosomal stability signature for various disease states, which allows our technology to make predictions related to health outcomes.
MedicalResearch.com: How does your platform assist health care providers in personalizing and managing patient care?
Response: The 3D Signatures tests help clinicians better identify an individual patient’s status. Our blood-based prostate cancer test is a great example of how 3D Signatures could significantly impact patient care. The test is both a highly accurate and minimally invasive risk-assessment and monitoring platform, with significant potential benefits over existing testing options. Recent results from a pilot study, that followed 50 men who had undergone radical prostatectomy, demonstrate that TeloViewTM could correctly predict the status/aggressiveness of disease in every single patient. The post-surgical assessment of the patients’ prostate glands showed that 29 of the 50 patients underwent unnecessary removal of their prostate. Each of these 29 men could have avoided surgery at that time, and the risks of adverse complications that often result, had the 3D Signatures tests been part of their clinical care options beforehand. This is highly personalized medicine with a significant impact on patients’ lives.
MedicalResearch.com: What should readers take away from your report?
Response: 3D Signatures is approaching biomarkers from an unconventional perspective. Our technology is not chasing sequence alterations in the genome, transcriptome, or proteome. It is measuring the overall level of structural disturbance or disorganization in the genome. It’s proving to be a very powerful predictor and appears to be a universal biomarker.
MedicalResearch.com: Is there anything else you would like to add?
Response: TeloViewTM is a true platform technology, with impressive results already across 14 diseases. Our top five priority indications in development include prostate cancer, lung cancer, and Alzheimer’s disease – very large markets with critical unmet needs. The business case is compelling, and the potential benefit to patients is enormous.™™™™™
View the YouTube Video on 3D Telomere Technology
Jason Flowerday is CEO and Director of 3D Signatures (www.3dsignatures.com), a novel personalized medicine company with a proprietary software platform based on the three-dimensional analysis of a patient’s individual chromosomal arrangement – or signature. Flowerday has two decades of executive life sciences management and start-up experience. Prior to joining 3D Signatures, he worked at two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and U.S.-based Johnson and Johnson before expanding his successful career into leading specialty pharmaceutical, biotech and device companies in their pursuit of growth and capital. Jason is also a Director of Aequus Pharmaceuticals (TSX-V: AQS), which allows him to leverage his network and apply his specialty pharma experience.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.